Rosetta Genomics, Ltd. (NASDAQ: ROSG), an innovative molecular diagnostics company, utilizes microRNAs, a collection of recently discovered non-coding control genes, to develop a broad array of tests for cancers and women’s health indications. These non-coding genes have demonstrated to be highly sensitive and tissue specific biomarkers. The company’s early recognition of microRNAs’ vast potential has led to great discovery and has the establishment of a leading intellectual property (IP) portfolio. For further information, visit the Company’s web site at www.rosettagenomics.com.
- 18 years ago
QualityStocks
Rosetta Genomics, Ltd. (NASDAQ: ROSG)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Forward Industries Inc. (NASDAQ: FWDI) Optimizes Capital Strategy with Strategic Buyback
Forward Industries (NASDAQ: FWDI) builds, operates, and manages a large-scale Solana (SOL) treasury, and is backed…
-
QualityStocksNewsBreaks – Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) Delineates High-Priority REE Zones at Atikokan
Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising. Powermax Minerals (CSE:…
-
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights
The scale and consequences of cardiovascular disease reinforce why innovation in this space remains essential.…